Related Experiment Video
Updated: Aug 4, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Opposed Behavioural Outputs of Increased Dopamine Transmission in Prefrontocortical and Subcortical Areas: A Role for
P. Vezina1, G. Blanc, J. Glowinski
1Chaire de Neuropharmacologie, INSERM U. 114, Collège de France, 11, place Marcelin Berthelot, 75231 Paris Cedex 05, France.
Abstract:
The possibility that the dopaminergic neurons innervating the medial prefrontal cortex (mPFC) can inhibit locomotor behaviour has been suggested in several studies. The evidence remains indirect, however, because the manipulations tested aimed exclusively at permanently depleting mPFC dopamine. Here we demonstrate in rats that acute increases in dopamine transmission in this site by local injections of amphetamine inhibit the known locomotor-activating effects of amphetamine in the nucleus accumbens (N.Acc.). Further, intra-mPFC injections of the D-1 dopamine receptor antagonist SCH-23390, but not other dopamine antagonists with greater affinities for noradrenergic, serotonergic and D-2 dopamine receptors, enhanced the locomotion induced by intra-N.Acc. amphetamine. These findings provide direct evidence for the inhibition of locomotor activity by mPFC dopamine and suggest that it is acting at D-1 dopamine receptors in this site.
Insights
Dopamine in the medial prefrontal cortex (mPFC) inhibits locomotion. Blocking D-1 dopamine receptors in the mPFC enhances amphetamine-induced locomotion, providing direct evidence for dopamine's inhibitory role in motor behavior.
Area of Science:
- Neuroscience
- Behavioral Neuroscience
- Psychopharmacology
Background:
- Previous studies suggested dopamine in the medial prefrontal cortex (mPFC) inhibits locomotor behavior, but evidence was indirect.
- Prior research primarily used permanent dopamine depletion, limiting the understanding of acute dopamine function.
Purpose of the Study:
- To provide direct evidence for the inhibitory role of medial prefrontal cortex (mPFC) dopamine on locomotor activity.
- To investigate the specific dopamine receptor subtype involved in this inhibitory pathway.
Main Methods:
- Rats received local injections of amphetamine into the mPFC to acutely increase dopamine transmission.
- Locomotor activity was assessed following mPFC amphetamine administration.
- The effects of intra-mPFC injections of the D-1 dopamine receptor antagonist SCH-23390 on locomotion were examined, alongside other dopamine receptor antagonists.
Main Results:
- Acute increases in dopamine transmission in the mPFC by amphetamine injections inhibited the locomotor-activating effects of amphetamine in the nucleus accumbens (N.Acc.).
- Intra-mPFC administration of SCH-23390, a D-1 dopamine receptor antagonist, enhanced locomotion induced by intra-N.Acc. amphetamine.
- Other dopamine antagonists with different receptor affinities did not produce this enhancement, indicating D-1 receptor specificity.
Conclusions:
- These findings provide direct evidence that dopamine acting in the mPFC inhibits locomotor activity.
- The results strongly suggest that this inhibitory effect is mediated via D-1 dopamine receptors within the mPFC.
Related Concept Videos
Desensitization and Tachyphylaxis
Several...
Neurochemical Transmission: Sites of Drug Action
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.

